ABSTRACT: Drug design studies targeting one of the primary toxic agents in Alzheimer's disease, soluble oligomers of amyloid β-protein (Aβ), have been complicated by the rapid, heterogeneous aggregation of Aβ and the resulting difficulty to structurally characterize the peptide. 
■ INTRODUCTION
Alzheimer's disease (AD) is a degenerative brain disorder and a major cause of dementia for which no cure is known. Currently, >35 million people worldwide are believed to suffer from the disease and with the aging of the population this number is expected to increase by a factor of 3−4 over the next 40 years. 1 AD is characterized by two pathological hallmarks, extracellular deposits composed primarily of amyloid β-protein (Aβ) fibrils and intracellular, hyperphosphorylated tau fibrils. While the identity of the molecular species responsible for the initiation of AD pathology has been debated historically, genetic evidence from early onset familial AD, 2−5 and experimentally observed neurotoxicity of Aβ, 6−11 have indicated that Aβ assembly into β-sheet rich aggregates is a crucial, early stage, neurotoxic element in AD.
Although Aβ is an important neurotoxin in the etiology of AD, the heterogeneous nature of Aβ assemblies has made it difficult to study particular toxic Aβ oligomers individually. An early hypothesis of Aβ toxicity stated that the energetically stable, insoluble Aβ fibrils were the primary pathologic species. 12 However, a large body of evidence demonstrated poor correlation between fibril content and disease severity, thus potentially contradicting the original amyloid fibril hypothesis. 13−16 Instead, evidence connecting synaptotoxicity and early cognitive deficits to soluble Aβ oligomers has emerged. 9, 17, 18 Still, because of the rapid aggregation kinetics of Aβ and the existence of Aβ oligomers in dynamically changing mixtures, it has been difficult to elucidate the exact mechanism of assembly and the relationship between specific oligomer structures and their toxic activity. Bitan et al. have used photo-induced crosslinking of unmodified proteins (PICUP) to demonstrate the rapid equilibration of monomers and oligomers in freshly prepared Aβ, with distinct oligomer size distributions for Aβ 40 and Aβ 42 . 19 Recently, the relationship between oligomer order and toxicity was elucidated for Aβ40 monomer through tetramer using PICUP-stabilized oligomers. 20 Nonetheless, testing the biological activity of single oligomeric Aβ species has been highly challenging.
An additional consequence of the heterogeneous composition of Aβ assemblies is the difficulty determining the structure of soluble Aβ oligomers under physiological conditions. Traditional high-resolution methods, such as X-ray crystallography and solution-state NMR spectroscopy, have been unsuccessful at determining the structure of the pathologically and physiologically relevant soluble Aβ oligomers. Efforts have been made to stabilize low-molecular-weight oligomers, but to date, high-resolution structures of Aβ oligomers are not available. To gain insight into the structural features of Aβ oligomers and the mechanisms by which they cause neurotoxicity, more information is needed.
Toward this end, we have previously reported the results of a Markov state model molecular dynamics (MSM-MD) simulation of four C-terminal fragments of Aβ 42 at physiological concentrations. 21 Because of the strong dependence of aggregation kinetics on the exact amino acid sequence of the C-terminus, C-terminal fragments of Aβ 21−43 were used in the simulation. The study revealed that Aβ trimers were a semistable state in the aggregation pathway, in which monomers contained a β-turn in the C-terminus. Similar structural motifs containing a C-terminal β-turn had been previously predicted in coarse-grained simulations. 22 On the basis of these results, a Gly 37 →D-Pro substitution was predicted to stabilize the β-turn. Given that this turn is not seen in any proposed structure of Aβ fibrils, it was hypothesized that the Gly 37 →D-Pro substitution would stabilize soluble forms of Aβ 42 .
Recently, we have reported experimental studies of the structure and behavior of an Aβ analogue containing both To further evaluate the effect of the Gly 37 →D-Pro substitution on fibril formation, peptide preparations were imaged using transmission electron microscopy (TEM) at the same time point as the ThT fluorescence measurement. Aβ 42 showed extensive fibril formation with codeposition of amorphous aggregates (Figure 2A,B Figure 3 ). This result demonstrates that any D-proline Figure 5A ). In doing so, molecules mimicking the β-turn structure and recapitulating hydrogen-bonding interactions were selected. The top 100 scoring hits from the Maybridge Screening Database were purchased and investigated for their ability to reduce Aβ 42 aggregation.
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The compounds were screened in a single-dose ThT aggregation assay (data not shown). Compounds identified as potential hits were further evaluated in a dose−response ThT aggregation assay. Of these compounds, 4- 
Figure 5B,C). 1 was found to inhibit WT Aβ 42 aggregation as read by ThT fluorescence with an IC 50 of 13 μM.
Characterization of the Effects of 1 on WT Aβ 42 Aggregation. We then evaluated the effect of 1 on the secondary structure of aggregated Aβ 42 by CD. In initial scans, identically prepared solutions of WT Aβ 42 and a 1:1 ratio of drug/Aβ 42 showed a minimum absorbance around 197 nm and were otherwise characteristic of a statistical coil conformation ( Figure 6A ). Over the course of the five-day aggregation, the WT Aβ 42 spectra shifted to have an absorbance maximum around 196 nm and minimum at 217 nm, indicating the transition of the WT peptide from a statistical coil to β-sheet rich conformation. In comparison, the CD spectrum of the 1:1 solution did not change over the course of the experiment and remained consistent with a random coil structure.
To supplement our data on the effect of 1 on Aβ 42 fibril formation, we investigated the formation of fibrils by TEM in solutions of the compound at a 1:1 ratio to Aβ 42 . As reported above, WT Aβ 42 forms mature fibrils over the course of a fourday aggregation experiment (Figure 4A,B) . However, in the 1:1 mixture, no fibrils were observed and only amorphous aggregates were seen ( Figure 6B ]-Aβ 42 showed only 14% decrease in viability at this concentration. 1 also showed a dose-dependent increase in toxicity, reducing cell viability by 40% at 50 μM. (Figure 6 ) Stability Assessment of 1 and Identification of Active Fragment. Given the intriguing effects of 1 on Aβ 42 , we sought to verify its stability under experimental conditions by LC-MS. We found that upon entering an aqueous environment 1 reached an equilibrium with several degredation products (Figure 8 ). Dechlorination of 1 at the para chlroine, followed by epoxidation, yields a product with a mass 20 g/mol lighter than 1, identified as 1−20 (mass spectra and NMR available in the Supporting Information). Either 1 or 1−20 undergoes hydrolysis of the imine to yield the degredation products 2 or 2−20, respectively, and 3. Unexpectedly, mass chromatograms and UV spectra of samples incubated up to 24 h were identical within error, indicating that the equilibrium does not trend toward any product on time scales relevant to these experiments. When compound 2 was analyzed alone with the same protocol, the product 2−20 was not identified, suggesting that the dechlorination/epoxidation occurs only in the parent compound, 1.
To assess the activity of the fragments relative to compound 1, we obtained 2 and 3 to evaluate in ThT assays. While compound 3 was found to be inactive (data not shown), compound 2 exhibited a dose-dependent inhibition of Aβ 42 aggregation ( Figure 9) . Interestingly, the inhibition of Aβ 42 by 2 exhibited notably different kinetics in comparison to 1. At t = 0 d (Figure 9A ), the IC 50 of 1 as measured by percent of flourescence of an untreated control was 62 μM and the IC 50 of 2 was 30 μM. Over the course of the four-day aggregation, 1 increased in efficacy in comparison to control with an IC 50 of 13 μM at t = 4 d ( Figure 9B ). Conversely, compound 2 showed similar efficacy after the aggregation period, with an IC 50 of 23 μM at t = 4 d.
■ DISCUSSION
In our effort to design a stable oligomer of Aβ 42 , we have predicted 21 that the substitution Gly 37 →D-Pro would result in enhanced β-hairpin formation and increased stability of loworder oligomers, particularly trimers. Here, our PICUP results confirmed these computational predictions. demonstrating a 70.7 ± 5.5% increase in trimer abundance of [Nle 35 ,D-Pro 37 ]-Aβ 42 compared to Aβ 42 (Figure 4) . The CD, Thioflavin T, and TEM experiments demonstrated that the Gly 37 →D-Pro substitution prevented formation of β-sheet-rich fibrils and promoted formation of amorphous assemblies devoid of regular secondary structure elements (Figures 1−3) . The data suggest that the β-turn stabilized by the Gly 37 →D-Pro mutation either (a) stabilizes the small, soluble oligomers to such a degree as to prohibit further aggregation into fibrils and/or (b) the (Figures 1,3) . At a 1:1 ratio, aggregation as read by ThT was reduced by 60% when compared to WT peptide alone. In TEM images, fibrils were reduced in the solution containing a mixture of [ 42 were used in a ligand-based drug discovery effort. Using this approach, we discovered 1 and found that it inhibited Aβ 42 β-sheet formation with an IC 50 of 13 μM over a four-day aggregation ( Figure 5) . Results from CD and TEM experiments were consistent with the ThT data and indicated that 1 completely inhibited Aβ 42 fibril and β-sheet formation at a 1:1 molar ratio (Figure 6 ). Considering the results of the LC-MS stability assessment in combination with the ThT studies with compound 2, the substructure represented by 2 clearly is the primary fragment of 1 responsible for inhibition of Aβ 42 . Although 3 does not inhibit aggregation on its own, the addition of fragment 3 to fragment 2 (yielding 1) significantly alters the kinetics of the aggregation in comparison to 2 alone. The data suggest that 2 has a faster rate of association with Aβ 42 in comparison to 1.
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Both ]Aβ 42 based on a structural motif observed in the structure of the Aβ 42 trimer predicted from molecular dynamics simulations. Recently, we have reported solution NMR structures confirming the existence of the predicted β-hairpin, and the data herein demonstrate a 70% increase in the relative population of the trimer in freshly prepared solutions. The use of computation to predict the structure of a stable species in a heterogeneous aggregation pathway and guide the development of an experimental investigation is notable and suggests a methodology for developing aggregation inhibitors for other amyloid-related diseases, which are complicated due to a lack of structural information. 1,1,1,3,3,3 -hexafluoro-2-propanol (HFIP) (Sigma no. 325244) to a concentration of 1 mg/mL and incubated for 2 h at room temperature. After aliquoting the solution, samples were covered with Parafilm in which holes were poked. The solvent was evaporated using a SpeedVac for 1 h and the dry peptide films stored at −80°C.
Immediately before experiments, samples were dissolved in DMSO (Sigma no. D2438), Biotechnology Performance grade) at 2 mM and sonicated for 5 min. The peptide solutions were diluted with PBS, pH 7.4 (GIBCO no. 10010) to the desired concentration. Final DMSO concentration was kept below 3%. For all other experiments, peptides were prepared as described previously. 28 Dried peptide films were dissolved by adding sequentially 10% of the final volume 60 mM NaOH, 45% water, and 45% 20 mM NaH 2 PO 4 buffer. After dissolution in 60 mM NaOH, peptides were sonicated for 1 min in a bath sonicator. Peptide concentration was measured by Bradford protein assay (Bio-Rad) or quantitative amino acid analysis and was generally 70−80% of the nominal concentration. Peptide mixtures were prepared immediately prior to the beginning of experiments.
Compounds were purchased from the Maybridge Screening Collection (Maybridge Chemical Company, Cornwall, UK) and Sigma. Compounds were dissolved in DMSO to 10 mM and then diluted with PBS to the desired concentration. Purity of the compounds was assessed by NMR, and the degredation of the parent compound was investigated by LC-MS. For MTT and CD experiments, which are sensitive to the presence of DMSO, 1 was dissolved to 10 mM in NaOH and then diluted further with PBS.
PICUP/SDS-PAGE. Photo-induced cross-linking of unmodified proteins (PICUP) was performed as described previously. 25 Briefly, 1 μL of 40 mM ammonium persulfate (APS, Aldrich) and 1 μL of 2 mM tris(2,2′-bipyridyl)dichlororuthenium(II) (Ru(Bpy)) (Aldrich) were added to 18 μL of 25 μM WT Aβ 42 sample in a clear PCR tube. Irradiation was carried out for 1 s. The cross-linking reaction is quenched immediately by adding 1 μL of 1 M DTT and 10 μL of Tricine sample buffer (Invitrogen). Samples are then analyzed using 1 mm thick, 10−20% Tris-Tricine gradient gels (Invitrogen) and silver stained (SilverXpress, Invitrogen). Following air drying, gels were analyzed using ImageJ. Reported values are from averaging of three separate gels.
Circular Dichroism. Samples of 25 μM WT peptide, in the absence or presence of [Nle 35 ,D-Pro 37 ]Aβ 42 or 1 were incubated at 37°C with continuous agitation using an orbital shaker at 200 rpm. Spectra were recorded every 24 h during 5 days using a J-810 spectropolarimeter (Jasco, Easton, MD) equipped with a thermostable sample cell at 37°C using 1 mm path-length cuvettes. Spectra were collected from 190 to 260 nm with 1 s response time, 100 nm/min scan speed, 0.2 nm resolution, and 1 nm bandwidth. Spectra were averaged after background subtraction.
Thioflavin T Fluoresence. Samples were incubated at 37°C for four days in triplicates with shaking. Then 10 μL samples were added in black, flat-, and clear-bottom 96-well plates (Corning no. 3631) to 190 μL of 25 μM Thioflavin T (Sigma no. T3516) in 50 mM glycine, pH 8 (Fisher no. G48−212). After a 5 min incubation with the dye, the fluorescence of ThT was measured using a Spectromax M5 fluorometer (Molecular Devices) at an excitation wavelength of 446 nm and emission at 490 nm. Science, Hatfield, PA) for 2 min and stained with 7 μL of 1% uranyl acetate. The samples were analyzed using a transmission electron microscope JEM1200-EX (JEOL).
MTT Assay. MTT assays were conducted as previously reported. 26 Rat pheochromocytoma (PC-12) cells were maintained in F-12 nutrient mixture with Kaighn's modification (F-12K) with 15% heatinactivated horse serum and 2.5% FBS at 37°C in an atmosphere of 5% CO 2 . For cell viability assays, cells were plated in 96-well plates at a density of 30000 cells per well in differentiation media (F-12K, 0.5% FBS, 100 μM nerve growth factor) and maintained for 48 h.
To assess the biological activity of Aβ 42 , [Nle 35 ,D-Pro 37 ]Aβ 42 , and 1, solutions were prepared as indicated above and diluted into RPMI media to yield concentrations 10 times higher than experimental concentrations. Aliquots of 10 μL were added to PC-12 cells to yield final concentrations of 10 μM WT Aβ 42 and incubated for 15 h. Cell viability was assessed qualitatively by visual observation and quantitatively by the CellTiter 96 nonradioactive cell proliferation assay (Promega). Briefly, 15 μL of dye solution was incubated with the cells for 3 h. Then 100 μL of solubilization/stop solution was added and the plates were incubated overnight in the dark to ensure complete solubilization. Plates were read by using a Synergy HT microplate reader (BioTek), and the absorbance at 570 nm (formazan product) minus the absorbance at 630 nm (background) was recorded. At least three independent experiments with six replicates (n = 18) were carried out, and the results were averaged.
Virtual Screening. A representative structure from the previously reported NMR studies into the [Nle 35 ,D-Pro 37 ]Aβ 42 peptide was used as a basis for the ligand-based screen. Residues 35−40 were extracted from the full structure, and side chain atoms were deleted except for the proline atoms. The Maybridge Screening Collection was used as a screening database. Molecules were stripped of salts, and conformers of the remaining molecules were created using Omega (version 2.3, OpenEye Scientific Software). The screening database was then compared to the modified peptide structure using the program ROCS (version 2.3, OpenEye Scientific Software). The Explicit Mills Dean force field was used, with the exception that ring interactions were turned off. The top 100 compounds ranked by combo Tanimoto after optimization by shape and color and were selected for evaluation by ThT. Compound 1 was ranked 48th out of 56897 compounds screened (details available as Supporting Information). 
